Ketamine for Depression: FDA-Approved vs. Off-Label Risks & What You Need to Know

Treatment-Resistant Depression

Ketamine for Depression: What's FDA-Approved, What's Off-Label, and What the At-Home Boom Isn't Telling You

One version is an FDA-approved monotherapy delivered under two hours of medical observation. Another is mailed to your door in doses that vary sixteen-fold between patients. Knowing which is which matters more than almost anything else you'll read about depression this year.

Reviewed by the clinical team at East Coast Telepsychiatry  |  Evidence-based patient education  |  Reading time: 13 minutes

If you've tried two or more antidepressants and still feel the same weight pressing down, you are not an outlier and you are not a lost cause. You are one of roughly a third of people with major depression for whom the standard medications simply don't produce remission. And you are almost certainly the person the ketamine industry is advertising to.

That advertising is not all wrong. Something genuinely important happened in psychiatry over the last decade: for the first time in more than thirty years, a drug arrived that works on an entirely different brain system than every SSRI and SNRI before it, and it works in hours rather than weeks. In January 2025, the FDA went further and approved esketamine as a standalone treatment for treatment-resistant depression — the first and only monotherapy ever approved for that condition.

But the same decade produced a parallel market of at-home ketamine subscriptions, compounded lozenges, and telehealth prescribing that operates almost entirely outside the evidence base the approval was built on. Both of those things are called "ketamine." They are not the same product, the same dose, the same setting, or the same level of safety. This article is about telling them apart.

~1 in 3Adults with major depression who don't respond adequately to standard antidepressants 86%Still without remission after trying a third antidepressant in the landmark STAR*D trial 22.5%Remission at 4 weeks on esketamine monotherapy vs 7.6% on placebo 84 mgMaximum per-session dose of FDA-approved esketamine, under direct observation

What Does "Treatment-Resistant Depression" Actually Mean?

Short answer

Treatment-resistant depression (TRD) generally means major depressive disorder that hasn't responded adequately to at least two different antidepressants, each taken at an adequate dose for an adequate length of time — usually six to eight weeks. It is a description of how your illness has responded to treatment so far. It is not a diagnosis of a more severe or more permanent disease.

That definition matters because the word "resistant" does a lot of unearned emotional damage. People hear it as a verdict on themselves — that their depression is stronger, stranger, or more hopeless than other people's. Clinically, it means something narrower and far less grim: the first two things we tried didn't work well enough, so we move to the next tier of options.

The scale of the problem is well documented. The National Institute of Mental Health estimates roughly 21 million U.S. adults experience at least one major depressive episode in a given year. The STAR*D trial — still the largest real-world antidepressant study ever run — found that remission rates fell sharply with each successive medication trial, and that by the fourth step, the large majority of participants had not reached remission.

There is one caveat worth taking seriously before assuming the label applies to you. A meaningful share of "treatment-resistant" depression turns out on careful re-evaluation to be something else: undiagnosed bipolar disorder (where antidepressants alone often fail or backfire), an untreated anxiety disorder or ADHD running underneath, a thyroid or sleep disorder, ongoing substance use, or a dose that was never actually pushed to a therapeutic level. Before escalating to an interventional treatment, a thorough diagnostic re-look is not a delay — it's often the fastest route to the thing that finally works.

If you're unsure where you stand, a structured self-screening is a reasonable first step. Our free mental health screenings include the PHQ-9 for depression severity and the MDQ, which screens for the bipolar features that frequently hide inside a depression diagnosis.

How Does Ketamine Work Differently From an Antidepressant?

Short answer

SSRIs and SNRIs act on serotonin and norepinephrine and typically take four to eight weeks to show benefit. Ketamine and esketamine act on the brain's glutamate system by blocking NMDA receptors, and can produce measurable improvement within 24 hours. The FDA's own labeling states that the precise mechanism by which esketamine produces its antidepressant effect is unknown.

Every widely prescribed antidepressant since the late 1980s has worked, broadly, on monoamines — serotonin, norepinephrine, dopamine. Ketamine doesn't. It is an NMDA receptor antagonist, which places it in the glutamate system, the brain's primary excitatory signaling network. The leading hypothesis is that this triggers a rapid cascade of synaptic growth — new connections forming in regions of the prefrontal cortex that tend to be atrophied in chronic depression.

That's a hypothesis, not a settled fact, and it's worth being honest about it: the FDA label for esketamine says outright that the mechanism is unknown. What is not in dispute is the timeline. Where an SSRI asks you to wait a month and a half to find out whether it helps, ketamine's effects — when they occur — show up within a day or two. For someone who has spent years cycling through six-week trials, that compression is the entire point.

FDA-approved esketamine is administered in a certified healthcare setting with at least two hours of direct monitoring after each dose — a requirement that is part of the treatment, not bureaucratic overhead.

Ketamine vs. Esketamine: What's the Actual Difference?

Short answer

Esketamine (brand name Spravato) is a nasal spray that is FDA-approved specifically for treatment-resistant depression and must be given in a certified clinic under monitoring. Racemic ketamine — the IV or compounded form marketed by most infusion clinics and at-home programs — is FDA-approved only as an anesthetic. Every psychiatric use of racemic ketamine is off-label.

This distinction is the single most consequential thing on this page, and it is routinely blurred in marketing copy that uses the two words interchangeably.

	Esketamine (Spravato)	Racemic ketamine (IV, IM, compounded oral)
FDA status	Approved 2019 as an add-on for TRD; approved January 21, 2025 as the first and only monotherapy for TRD in adults	Approved only as an anesthetic. All psychiatric use is off-label. Schedule III controlled substance
Setting & monitoring	Certified healthcare setting under a REMS program; patient observed at least 2 hours after each dose; maximum 84 mg per session	Varies enormously — from a monitored infusion suite to a lozenge mailed to your home with no in-person supervision at all
Insurance	Commonly covered, though prior authorization and documented failed trials are usually required	Rarely covered for psychiatric use because it is off-label; typically paid out of pocket
Evidence base	Multiple registration trials plus a dedicated Phase 4 monotherapy trial supporting the 2025 approval	Genuine research support for monitored IV administration; very little controlled evidence for unsupervised at-home oral dosing

The 2025 monotherapy approval rested on a Phase 4 randomized trial (NCT04599855) in which 22.5% of participants taking esketamine alone reached remission at four weeks, defined as a MADRS score of 12 or below, compared with 7.6% on placebo. Separation from placebo appeared as early as 24 hours. Those numbers deserve to be read carefully in both directions: tripling the remission rate in a population that has already failed multiple medications is a real clinical achievement, and a 22.5% remission rate also means that roughly three out of four people in that trial did not reach remission on it.

Comparative data has been somewhat kinder. A 2023 head-to-head study found esketamine associated with a substantially higher likelihood of remission at eight weeks than quetiapine augmentation, a standard alternative. But the drug has critics inside psychiatry as well — a published critique titled "Esketamine for treatment resistant depression: a trick of smoke and mirrors?" argues that the effect sizes in the registration trials are more modest than the marketing implies and that the blinding was imperfect, because a dissociating drug is fairly easy to distinguish from placebo. Both of those views can be held at once, and a good prescriber will tell you about both.

Does It Actually Work?

Short answer

For a meaningful minority of people with treatment-resistant depression, yes — and faster than anything else available. Roughly one in five reach full remission on esketamine monotherapy within four weeks, with more experiencing partial response. It is not a cure, the benefit requires ongoing dosing to maintain, and most people who try it will still need additional treatment.

The honest framing is that ketamine-class treatments moved something that had been stuck. Before 2019, a person who had failed several antidepressants had a fairly short menu: augmentation strategies, older MAOIs, TMS, or ECT. Adding a rapid-acting option with a different mechanism was a genuine expansion of that menu.

What it is not is what the direct-to-consumer ads suggest. Effects are not permanent. Maintenance dosing is typically required, often indefinitely, and the long-term consequences of years of repeated dosing are not well characterized — the trials that supported approval ran for weeks and months, not decades. Anyone telling you they know what ten years of maintenance ketamine does to the bladder, cognition, or dependence risk is telling you something the data does not yet support.

The At-Home Ketamine Problem

During the pandemic, federal telehealth flexibilities allowed controlled substances to be prescribed without an in-person evaluation. A large at-home ketamine industry grew into that opening, typically shipping compounded oral or sublingual ketamine directly to patients on a subscription model.

A STAT News investigation published in March 2026 documented what that looks like in practice: patients self-reporting doses ranging from 50 mg to 800 mg — a sixteen-fold variance across a population taking nominally the same treatment — and people managing frightening dissociative episodes by asking strangers on Reddit rather than a clinician.

84 mgMaximum per-session esketamine dose under the FDA-approved protocol, with 2+ hours of direct observation 50–800 mgSelf-reported dose range among at-home telehealth ketamine patients, largely unobserved

The FDA has issued explicit warnings about compounded ketamine products, including at-home formulations, noting that compounded drugs do not undergo FDA review for safety, effectiveness, or quality, and flagging risks of sedation, dissociation, and inadequate monitoring when these are used outside a healthcare setting.

The agency has since moved from advisories to enforcement. In June 2026 the FDA issued a round of warning letters to online ketamine sellers marketing unapproved products directly to consumers.

None of this means every at-home program is reckless, and some operate with real screening and follow-up. It means the label "ketamine treatment" tells you almost nothing about the quality or safety of what you're being sold. The protocol is what matters.

What Are the Risks and Side Effects?

Short answer

The most common short-term effects are dissociation, dizziness, nausea, sedation, and transient blood pressure elevation — which is why post-dose monitoring exists. Longer-term concerns include bladder toxicity with heavy repeated use, potential for misuse given its Schedule III status, and cognitive effects that are not fully characterized. Ketamine is not appropriate for people with certain cardiovascular conditions, active psychosis, or a history of substance use disorder without careful evaluation.

Dissociation — a sense of detachment from your body, surroundings, or sense of time — is not a side effect in the incidental sense. It is an expected pharmacological effect of the drug at therapeutic doses, and for many people it is deeply unpleasant the first time it happens. In a monitored setting, a nurse is present, the experience is explained in advance, and it resolves within the observation window. Alone at home, at an unverified dose, with no one to tell you it's expected, it's a different event entirely.

Blood pressure rises transiently after dosing, which is the specific reason the REMS program requires observation rather than a handshake and a taxi home. Bladder toxicity — sometimes severe — is well documented in people who use ketamine heavily and chronically, largely from recreational-use literature, and its relevance to long-term maintenance dosing at therapeutic levels is an open question rather than a resolved one.

Ketamine is a Schedule III controlled substance under the Controlled Substances Act, meaning it carries recognized potential for abuse and dependence. For someone with a history of substance use disorder, that doesn't automatically rule it out, but it does mean the risk-benefit conversation is a genuinely different one and belongs with a prescriber who knows your full history.

Before escalating to an interventional treatment, a careful diagnostic re-evaluation often identifies something treatable that earlier trials missed.

What Else Works for Treatment-Resistant Depression?

Short answer

Ketamine is one option among several, and it is not automatically the first one to try. Diagnostic re-evaluation, augmentation strategies, TMS, ECT, older MAOI antidepressants, and structured psychotherapy all have evidence in treatment-resistant depression, and several are more accessible and less expensive.

Diagnostic re-evaluation

The highest-yield step. Unrecognized bipolar disorder, ADHD, trauma, thyroid dysfunction, sleep apnea, or a dose never pushed to therapeutic range explain a real share of apparent resistance.

Augmentation

Adding a second agent — lithium, an atypical antipsychotic, thyroid hormone, or bupropion — to an existing antidepressant rather than switching. Well-studied and often effective.

TMS

Transcranial magnetic stimulation is non-invasive, FDA-cleared for depression, requires no sedation, and is widely insurance-covered. Typically a several-week course of outpatient sessions.

ECT

Still the most effective treatment available for severe depression, with response rates exceeding anything else. Modern ECT bears little resemblance to its reputation, though cognitive side effects are real.

MAOIs

An older class with genuine efficacy in atypical and resistant depression. Underused because of dietary restrictions, but for the right patient they remain a legitimate and often overlooked option.

Structured psychotherapy

CBT, behavioral activation, and interpersonal therapy have evidence in resistant depression, particularly combined with medication. Not a substitute for biological treatment, but rarely optional either.

You can read more about how we approach depression and related diagnoses on our conditions we treat page.

7 Questions Worth Asking Any Ketamine Provider

1. Is this esketamine (Spravato) or racemic ketamine? If the answer is vague, that itself is information.
2. Where will I be during and after dosing, and who will be with me? An answer that ends with "at home, alone" deserves careful scrutiny.
3. What exact dose, and how was it determined? A provider should be able to explain the rationale, not just the number.
4. Who reviewed my diagnosis before recommending this? Ask specifically whether bipolar disorder has been ruled out.
5. What happens if it doesn't work? A provider with only one treatment to sell has only one recommendation to give.
6. What's the maintenance plan and what does it cost long-term? Including what happens if you stop.
7. Who do I reach at 2 a.m. if something goes wrong? There should be a real, specific answer.

Where to Find Reliable Information

• National Institute of Mental Health — Depression, for plain-language clinical overviews without a commercial interest.
• FDA guidance on compounded ketamine products, the agency's direct statement on at-home formulations.
• ClinicalTrials.gov, where you can read the actual protocols and outcomes behind any trial a clinic cites at you.
• SAMHSA National Helpline — free, confidential, 24/7 treatment referral at 1-800-662-4357.
• NAMI, for peer support and navigating care when you are too exhausted to navigate it alone.

Frequently Asked Questions

Is ketamine covered by insurance for depression?

Esketamine (Spravato) is commonly covered, though nearly always with prior authorization and documentation that you've failed at least two adequate antidepressant trials. Racemic ketamine infusions and compounded at-home ketamine are rarely covered for psychiatric use, because that use is off-label. Our insurance and cost page explains how coverage questions generally work.

Can I get ketamine treatment through telehealth?

The psychiatric evaluation, diagnosis, and follow-up care can absolutely happen through telehealth. The administration of FDA-approved esketamine cannot — it legally requires a REMS-certified in-person setting with at-home use expressly not permitted. Programs that mail compounded ketamine for unsupervised home use exist, but they operate outside the protocol the approval was based on.

How fast does it work?

Faster than any antidepressant class before it. In the monotherapy trial, separation from placebo appeared within 24 hours, and the primary remission endpoint was measured at four weeks. That said, rapid onset also means rapid offset — the benefit typically requires ongoing maintenance dosing rather than resolving the episode permanently.

Is the dissociation dangerous?

In a monitored clinical setting, dissociation is an expected, time-limited effect that resolves during the observation period, and staff are present specifically to manage it. The risk profile changes substantially when it happens unsupervised at an unverified dose, which is the core of the FDA's concern about compounded at-home products.

Should I try TMS before ketamine?

There is no universal sequence, and the right order depends on your history, urgency, insurance, and what you've already tried. TMS is non-invasive, widely covered, and requires no sedation or controlled substance, which makes it a reasonable earlier step for many people. Someone in acute crisis with severe symptoms may have different priorities. This is a conversation for a prescriber who knows your full record.

I've failed five antidepressants. Does that mean nothing will work?

No. It means the monoamine approach hasn't worked for you, which is a statement about one class of drugs — not about your prognosis. It's also the exact scenario where a fresh diagnostic look is most likely to change the plan, because five failed trials of the wrong treatment for the wrong diagnosis is a pattern with a fixable cause.

If You're in Crisis Right Now

Treatment-resistant depression carries elevated suicide risk, and exhaustion with treatment itself is one of the hardest parts of it. If you're having thoughts of harming yourself, call or text 988 to reach the Suicide & Crisis Lifeline, available 24/7 across the United States. You can also chat online at 988lifeline.org. If you're in immediate danger, call 911 or go to your nearest emergency department.

Reaching out during a bad night is not an overreaction. It's the thing that keeps options open until a better day arrives.

A Practical First Step

If you're weighing an interventional treatment, it helps to walk into that conversation with a clear picture of where your symptoms actually sit. Our free, confidential screening tools include the PHQ-9 for depression severity, the GAD-7 for co-occurring anxiety, and the MDQ for bipolar features — all of which shape whether ketamine is the right next move or a detour around something more treatable.

Screenings aren't diagnoses. What they do is give you and a clinician a shared starting point instead of a blank page.

Being Straight With You About What We Do

East Coast Telepsychiatry provides psychiatric evaluation, diagnosis, medication management, and ongoing care by video. We do not administer ketamine or esketamine. Esketamine requires a REMS-certified in-person healthcare setting with observation after every dose — no telehealth practice can provide that remotely, ours included, and any practice claiming otherwise is describing something other than the FDA-approved protocol.

What we can do is the part that determines whether that referral is the right one: a careful diagnostic evaluation, an honest review of what you've already tried and whether those trials were adequate, optimization of medications that may not have been given a fair test, and a referral to a certified center when interventional treatment is genuinely indicated. We'd rather tell you that plainly than let a page about ketamine end in a pitch we can't deliver on.

Related Reading

Conditions We TreatDepression, anxiety, bipolar disorder, ADHD, PTSD and more Free ScreeningsPHQ-9, GAD-7, MDQ and other validated self-assessments Our ProvidersBoard-certified psychiatric clinicians across the East Coast Insurance & CostWhat's covered and what care actually costs FAQsHow telepsychiatry works, start to finish More ArticlesEvidence-based mental health education

Treatment-Resistant Isn't the Same as Untreatable

Two failed medications is a data point, not a prognosis. A careful re-evaluation of your diagnosis and treatment history is often the step that finally changes the picture — and it's the step that should come before any interventional treatment, not after it.

Schedule an Evaluation Explore Support Options

Sources & Further Reading

1. U.S. Food and Drug Administration. Compounded Ketamine Products — agency risk communication on at-home and compounded formulations.
2. National Institute of Mental Health. Major Depression Statistics.
3. National Institute of Mental Health. Depression — Overview and Treatment.
4. ClinicalTrials.gov. NCT04599855 — Phase 4 esketamine monotherapy trial in treatment-resistant depression.
5. ClinicalTrials.gov. NCT05554627 — additional esketamine research in TRD.
6. Johnson & Johnson. Press releases on SPRAVATO® regulatory milestones, including the January 2025 monotherapy approval.
7. Gastaldon C, et al. "Esketamine for treatment resistant depression: a trick of smoke and mirrors?" Epidemiology and Psychiatric Sciences (PubMed).
8. STAT News. Investigative reporting on at-home telehealth ketamine dosing variance (March 2026).
9. U.S. Drug Enforcement Administration. Controlled Substances — Alphabetical Order, ketamine Schedule III listing.
10. American Journal of Managed Care. Coverage of esketamine comparative effectiveness and payer considerations.
11. UTHealth Houston, Department of Psychiatry. Academic research on treatment-resistant depression.
12. SAMHSA. National Helpline — 1-800-662-HELP (4357).

This article is for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and esketamine carry significant risks and are not appropriate for everyone; decisions about any treatment should be made with a qualified clinician who knows your full medical and psychiatric history. East Coast Telepsychiatry does not administer ketamine or esketamine. If you are experiencing a mental health emergency, call or text 988 or dial 911.